British Columbia Adds Humira Adalimumab to Biosimilar Switching Program

 British Columbia Adds Humira Adalimumab to Biosimilar Switching Program

British Columbia Adds Humira Adalimumab to Biosimilar Switching Program

Shots:

  • British Columbia and Health Minister Adrian Dix expand the biosimilar switching program to include Humira adalimumab and a new indication for Enbrel etanercept
  • The expansion of the biosimilar switching program demonstrated the province’s continued confidence in biosimilars to manage costs and fund innovative new therapies while supporting positive patient outcomes
  • BC continues to apply its biosimilar switching policy as new indications become available for marketed biosimilars, and patients taking Enbrel etanercept for the treatment of plaque psoriasis will transition to an etanercept biosimilar during the same period

Click here to­ read full press release/ article | Ref: Biosimilar | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post